Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Yuhan Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Yuhan Corporation - Product Pipeline Review - 2014', provides an overview of the Yuhan Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Yuhan Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Yuhan Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Yuhan Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Yuhan Corporation's pipeline products Reasons to buy - Evaluate Yuhan Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Yuhan Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Yuhan Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Yuhan Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Yuhan Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Yuhan Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Yuhan Corporation Snapshot 7 Yuhan Corporation Overview 7 Key Information 7 Key Facts 7 Yuhan Corporation - Research and Development Overview 8 Key Therapeutic Areas 8 Yuhan Corporation - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Yuhan Corporation - Pipeline Products Glance 16 Yuhan Corporation - Late Stage Pipeline Products 16 Phase III Products/Combination Treatment Modalities 16 Yuhan Corporation - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Yuhan Corporation - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Yuhan Corporation - Drug Profiles 21 (atorvastatin calcium + losartan potassium) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 (rosuvastatin + telmisartan) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (rosuvastatin + valsartan) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 bilastine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 YHD-001 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 YH-14618 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 YH-4808 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 YHD-1023 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 YHD-14642 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 (rosuvastatin + metformin) 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 YH-12852 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 YHB-14112 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 YH-1176 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 YH-1177 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 YH-14619 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 YH-14810 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 YH_Bio1 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 YH_Bio2 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 YH_Chem1 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 YH_Chem2 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 YH_Chem3 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 YH_Chem4 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 YH_Chem5 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Drug to Agonize PPAR for Type 2 Diabetes 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 YH-GKA 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Yuhan Corporation - Pipeline Analysis 46 Yuhan Corporation - Pipeline Products by Target 46 Yuhan Corporation - Pipeline Products by Route of Administration 48 Yuhan Corporation - Pipeline Products by Molecule Type 49 Yuhan Corporation - Pipeline Products by Mechanism of Action 50 Yuhan Corporation - Recent Pipeline Updates 52 Yuhan Corporation - Dormant Projects 54 Yuhan Corporation - Company Statement 55 Yuhan Corporation - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Yuhan Corporation - Key Manufacturing Facilities 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60
List of Tables Yuhan Corporation, Key Information 7 Yuhan Corporation, Key Facts 7 Yuhan Corporation - Pipeline by Indication, 2014 9 Yuhan Corporation - Pipeline by Stage of Development, 2014 11 Yuhan Corporation - Monotherapy Products in Pipeline, 2014 12 Yuhan Corporation - Combination Treatment Modalities in Pipeline, 2014 13 Yuhan Corporation - Partnered Products in Pipeline, 2014 14 Yuhan Corporation - Partnered Products/ Combination Treatment Modalities, 2014 15 Yuhan Corporation - Phase III, 2014 16 Yuhan Corporation - Phase II, 2014 17 Yuhan Corporation - Phase I, 2014 18 Yuhan Corporation - Preclinical, 2014 19 Yuhan Corporation - Discovery, 2014 20 Yuhan Corporation - Pipeline by Target, 2014 47 Yuhan Corporation - Pipeline by Route of Administration, 2014 48 Yuhan Corporation - Pipeline by Molecule Type, 2014 49 Yuhan Corporation - Pipeline Products by Mechanism of Action, 2014 51 Yuhan Corporation - Recent Pipeline Updates, 2014 52 Yuhan Corporation - Dormant Developmental Projects,2014 54 Yuhan Corporation, Other Locations 56 Yuhan Corporation, Subsidiaries 57 Yuhan Corporation, Key Manufacturing Facilities 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
